At the DNA level, methylation in the Keap1 promoter, epigenetic silencing of its targeted genes, or mutations present in the binding sites of Keap1–Nrf2 take place during cancer development, but also under selective pressure of different therapies. This evidence concerns the gene KEAP1 and cancer.